This report was first published by Endpoints News. To see the original version, click here
With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Roche’s breast cancer drug giredestrant is sitting pretty.
Management is hugely confident in the pill. CEO Thomas Schinecker said on a call with journalists Thursday it could become “our biggest-selling medicine that we’ve ever sold.”
您已阅读10%（455字），剩余90%（4163字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。